Loading organizations...
§ Private Profile · Boston, MA, USA
A biotechnology company developing novel therapeutics for cardiovascular diseases, heart failure, and arrhythmia.
Cardurion Pharmaceuticals is a biotechnology company in Boston developing novel therapeutics for major unmet needs in cardiovascular diseases, particularly heart failure and arrhythmia disorders. Operating additional research and development facilities in Shonan, Japan, the enterprise focuses its therapeutic pipeline on unique drug discovery programs, including the PDE9 inhibitor CRD-733 and a targeted CaMKII inhibitor. To support ongoing drug development and corporate expansion, the firm secured up to $300 million in private equity investment from Bain Capital Life Sciences and Bain Capital Private Equity. The organization established a strategic partnership with Takeda Pharmaceuticals, which provided a dedicated research team of twelve people and preclinical drug candidate licenses, alongside earlier venture capital backing from Polaris Partners. Cardurion Pharmaceuticals was founded in 2016 by medical doctors Michael Mendelsohn and Daniel Bloomfield to create treatments for patients suffering from cardiovascular conditions.
Cardurion Pharmaceuticals has raised $560.0M across 2 funding rounds.
Cardurion Pharmaceuticals has raised $560.0M in total across 2 funding rounds.
Cardurion Pharmaceuticals is a clinical-stage biotechnology company developing novel therapeutics for cardiovascular diseases, including heart failure and arrhythmias.[1][2][3] It focuses on two lead programs: the first-in-class PDE9 inhibitor CRD-750 for chronic heart failure (HFrEF and HFpEF), currently in Phase 2 trials with 640 patients, and the pioneering CaMKII inhibitor CRD-4730 for catecholaminergic polymorphic ventricular tachycardia (CPVT) and other indications, also in Phase 2.[1][2] The company serves patients with unmet needs in cardiovascular disease, addressing problems like hyperactivated signaling pathways that drive heart failure and arrhythmias through precision medicine and adaptive trial designs.[2] Headquartered in Burlington, Massachusetts, with research facilities in Shonan, Japan, Cardurion employs 50-74 people and has raised funding via seed, Series A, and Series B rounds from investors like Bain Capital and NEA to advance its pipeline and acquire assets.[4]
Recognized as one of Endpoints News' 11 most promising private biotechs of 2024 for its science, leadership, and strategy, Cardurion demonstrates strong growth momentum with expanding clinical programs and partnerships.[1]
Cardurion Pharmaceuticals was founded in 2017 by physician-scientists Michael E. Mendelsohn, M.D. and Daniel Bloomfield, M.D., experts in cardiovascular signaling pathways driven by a passion to develop novel treatments for cardiovascular patients.[1][3][4] The idea emerged from their world-class knowledge of targets like PDE9 and CaMKII, which play causal roles in heart failure and arrhythmias, filling gaps in existing therapies.[2] Early traction came through seed and Series A funding to launch the pipeline, followed by Series B to support Phase 2 trials for CRD-750 and CRD-4730, plus portfolio expansion.[4] Pivotal moments include becoming the first to advance a CaMKII inhibitor into clinical studies and earning Endpoints 11 recognition in 2024.[1][2]
Cardurion rides the trend of precision cardiovascular medicine, targeting hyperactivated pathways like PDE9 and CaMKII amid rising global heart disease burden, where current treatments fall short for HFrEF, HFpEF, and rare arrhythmias.[1][2] Timing aligns with biotech's shift to adaptive trials and novel inhibitors, enabling faster proof-of-concept in large markets like heart failure (affecting millions) and niches like CPVT.[2][4] Market forces favoring it include investor interest in high-unmet-need cardio assets, as seen in Series B funding and Endpoints recognition, plus Japan-U.S. facilities for global R&D efficiency.[1][4] It influences the ecosystem by pioneering CaMKII modulation, potentially unlocking treatments for atrial fibrillation and beyond, and validating signaling pathway targets for peers.[2]
Cardurion is poised to deliver Phase 2 readouts for CRD-750 and CRD-4730 in 2025-2026, potentially proving foundational therapies for heart failure and arrhythmias, with pipeline growth via new indications and acquisitions.[1][2][4] Trends like AI-driven discovery and combo therapies with guideline-directed care will shape its path, amplifying efficacy in underserved cardio segments.[2] Its influence may evolve from clinical pioneer to market leader if trials succeed, drawing more partnerships and setting standards for pathway-specific biotech innovation—reinforcing its mission to change the course of cardiovascular disease.[2]
Cardurion Pharmaceuticals has raised $560.0M in total across 2 funding rounds.
Cardurion Pharmaceuticals's investors include Ascenta Capital, Amorchem, Forbion, New Enterprise Associates, Bain Capital Life Sciences.
Cardurion Pharmaceuticals has raised $560.0M across 2 funding rounds. Most recently, it raised $260.0M Series B in July 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 1, 2024 | $260M Series B | Ascenta Capital | AmorChem, Forbion, NEW Enterprise Associates | Announced |
| Oct 27, 2021 | $300M Venture Round | Bain Capital Life Sciences | — | Announced |